Cybin's CYB003 Phase 3 MDD interim/topline readout hits its primary efficacy endpoint but FDA-facing analysts flag functional unblinding concerns within 11 weeks.

Cybin, a psychedelic medicine company, is running a large clinical trial of CYB003 — a modified version of psilocin, the active ingredient in magic mushrooms — for people with major depression. Within 11 weeks, the company is expected to announce results showing the drug actually works. But experts reviewing the data for the FDA (the US Food and Drug Administration, which decides whether new medicines can be sold) are likely to raise a specific worry: participants can probably tell whether they got the real drug or a placebo because the psychedelic experience itself is a giveaway, which makes the results harder to trust.

Deuterated psilocin still produces perceptual effects; blinding integrity is the recurring reviewer concern across all psychedelic NDAs. Efficacy likely; methodological caveats inevitable.